These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 23987158)
1. Anatomic extent of pelvic lymph node dissection: impact on long-term cancer-specific outcomes in men with positive lymph nodes at time of radical prostatectomy. Bivalacqua TJ; Pierorazio PM; Gorin MA; Allaf ME; Carter HB; Walsh PC Urology; 2013 Sep; 82(3):653-8. PubMed ID: 23987158 [TBL] [Abstract][Full Text] [Related]
2. Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping study. Heck MM; Retz M; Bandur M; Souchay M; Vitzthum E; Weirich G; Mollenhauer M; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Gschwend JE; Nawroth R Eur Urol; 2014 Aug; 66(2):222-9. PubMed ID: 23465520 [TBL] [Abstract][Full Text] [Related]
3. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. Lestingi JFP; Guglielmetti GB; Trinh QD; Coelho RF; Pontes J; Bastos DA; Cordeiro MD; Sarkis AS; Faraj SF; Mitre AI; Srougi M; Nahas WC Eur Urol; 2021 May; 79(5):595-604. PubMed ID: 33293077 [TBL] [Abstract][Full Text] [Related]
4. Fluorescence-supported lymphography and extended pelvic lymph node dissection in robot-assisted radical prostatectomy: a prospective, randomized trial. Harke NN; Godes M; Wagner C; Addali M; Fangmeyer B; Urbanova K; Hadaschik B; Witt JH World J Urol; 2018 Nov; 36(11):1817-1823. PubMed ID: 29767326 [TBL] [Abstract][Full Text] [Related]
5. Undetectable PSA after radical prostatectomy is more likely in low burden N+ prostate cancer patients when an extended lymph node dissection is performed. Ramírez-Backhaus M; Mir Maresma MC; Mascarós JM; Bertolo R; Hernández J; Gómez Ferrer A; Casanova-Ramón Borja J; Domínguez Escrig JL; Collado-Serra A; Calatrava Fons A; Rubio-Briones J Actas Urol Esp (Engl Ed); 2019 Nov; 43(9):480-487. PubMed ID: 31174878 [TBL] [Abstract][Full Text] [Related]
6. Extended versus limited pelvic lymph node dissection during bilateral nerve-sparing radical prostatectomy and its effect on continence and erectile function recovery: long-term results and trifecta rates of a comparative analysis. Hatzichristodoulou G; Wagenpfeil S; Wagenpfeil G; Maurer T; Horn T; Herkommer K; Hegemann M; Gschwend JE; Kübler H World J Urol; 2016 Jun; 34(6):811-20. PubMed ID: 26420596 [TBL] [Abstract][Full Text] [Related]
7. Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques. Yaxley JW; Dagher J; Delahunt B; Egevad L; Srigley J; Samaratunga H World J Urol; 2018 Jan; 36(1):15-20. PubMed ID: 29116393 [TBL] [Abstract][Full Text] [Related]
8. Surgeon-led prostate cancer lymph node staging: pathological outcomes stratified by robot-assisted dissection templates and patient selection. Altok M; Babaian K; Achim MF; Achim GC; Troncoso P; Matin SF; Chapin BF; Davis JW BJU Int; 2018 Jul; 122(1):66-75. PubMed ID: 29446205 [TBL] [Abstract][Full Text] [Related]
9. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833 [TBL] [Abstract][Full Text] [Related]
10. Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study. Preisser F; van den Bergh RCN; Gandaglia G; Ost P; Surcel CI; Sooriakumaran P; Montorsi F; Graefen M; van der Poel H; de la Taille A; Briganti A; Salomon L; Ploussard G; Tilki D; J Urol; 2020 Feb; 203(2):338-343. PubMed ID: 31437119 [TBL] [Abstract][Full Text] [Related]
11. Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis. Wettstein MS; David LA; Pazhepurackel C; Qureshi AA; Zisman A; Nesbitt M; Saba K; Herrera-Caceres JO; Fankhauser CD; Ahmad A; Hamilton RJ; Eberli D; Zlotta AR; Sulser T; Fleshner NE; Poyet C; Finelli A; Hermanns T; Kulkarni GS Prostate; 2021 Apr; 81(5):286-294. PubMed ID: 33599318 [TBL] [Abstract][Full Text] [Related]
12. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era. Dorin RP; Lieskovsky G; Fairey AS; Cai J; Daneshmand S Urol Oncol; 2013 Nov; 31(8):1441-7. PubMed ID: 22516714 [TBL] [Abstract][Full Text] [Related]
14. Association between Lymph Node Counts and Oncological Outcomes in Lymph Node Positive Prostate Cancer. Mandel P; Kriegmair MC; Bogdan K; Boehm K; Budäus L; Graefen M; Huland H; Tilki D Eur Urol Focus; 2017 Apr; 3(2-3):248-255. PubMed ID: 28753755 [TBL] [Abstract][Full Text] [Related]
15. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen ( Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951 [TBL] [Abstract][Full Text] [Related]
16. Extended pelvic lymphadenectomy for prostate cancer: will the previously reported benefits be reproduced in hospitals with lower surgical volumes? Lindberg C; Davidsson T; Gudjónsson S; Hilmarsson R; Liedberg F; Bratt O Scand J Urol Nephrol; 2009; 43(6):437-41. PubMed ID: 19707953 [TBL] [Abstract][Full Text] [Related]
17. Extended versus standard pelvic lymphadenectomy during robot-assisted radical prostatectomy: the role of extended template as an independent predictor of lymph node invasion with comparable morbidity burden. Mistretta FA; Boeri L; Grasso AA; Lo Russo V; Albo G; DE Lorenzis E; Maggioni M; Palmisano F; Dell'orto P; Bosari S; Rocco B Minerva Urol Nefrol; 2017 Oct; 69(5):475-485. PubMed ID: 28281741 [TBL] [Abstract][Full Text] [Related]
18. The Impact of Adding Sentinel Node Biopsy to Extended Pelvic Lymph Node Dissection on Biochemical Recurrence in Prostate Cancer Patients Treated with Robot-Assisted Radical Prostatectomy. Grivas N; Wit EMK; Kuusk T; KleinJan GH; Donswijk ML; van Leeuwen FWB; van der Poel HG J Nucl Med; 2018 Feb; 59(2):204-209. PubMed ID: 28747519 [TBL] [Abstract][Full Text] [Related]
19. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Briganti A; Karnes JR; Da Pozzo LF; Cozzarini C; Gallina A; Suardi N; Bianchi M; Freschi M; Doglioni C; Fazio F; Rigatti P; Montorsi F; Blute ML Eur Urol; 2009 Feb; 55(2):261-70. PubMed ID: 18838212 [TBL] [Abstract][Full Text] [Related]
20. Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment. Mandel P; Rosenbaum C; Pompe RS; Steuber T; Salomon G; Chun FK; Graefen M; Huland H; Tilki D World J Urol; 2017 Dec; 35(12):1833-1839. PubMed ID: 28828530 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]